India's Pharma Market Growth Driven by GLP-1 Therapies and Leading Companies
India's pharmaceutical market grew 10.7% year-on-year in August 2026, led by price increases, new product launches, and volume growth, with Zydus Lifesciences and Glenmark Pharma showing the highest growth. GLP-1 therapies, especially semaglutide generics, are driving anti-diabetes segment growth, with sales rising modestly. Kotak Institutional Equities projects India's GLP-1 market to reach Rs157 billion by 2032, with 6.6 million patients expected on GLP-1 therapies. Key companies like Eris, Torrent, Natco, Lupin, and Sun Pharma are positioned to benefit, though no single firm is expected to dominate the market.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (61/100). Lens Score 39/100.
Outlets measured: businessstandard, moneycontrol, moneycontrol. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–70/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
moneycontrol broke this story on 10 Sept, 05:43 am. Other outlets followed.